Clinical outcome according to RASI therapy in patients with IMR
| Treatment | Univariate analysis | Multivariate analysis | IPTW | |||||
| RASI(+) (n=395) | RASI(−) (n=156) | Unadjusted (95% CI) | P value | Adjusted HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |
| All-cause death | 34 (9) | 39 (25) | 0.27(0.17 to 0.43) | <0.001 | 0.44(0.27 to 0.72) | 0.001* | 0.43(0.25 to 0.74) | 0.002 |
| Cardiac death | 10 (3) | 21 (13) | 0.15(0.07 to 0.32) | <0.001 | 0.33(0.14 to 0.76) | 0.009* | 0.28(0.12 to 0.66) | 0.004 |
| Composite outcome† | 29 (7) | 31 (20) | 0.30(0.18 to 0.50) | <0.001 | 0.53(0.30 to 0.92) | 0.025‡ | 0.51(0.28 to 0.95) | 0.033 |
*Covariates include peak CK, Killip classification, serum creatinine, prior MI, moderate/severe MR and β-blocker.
†Cardiac death or heart failure.
‡Adjusted with hypertension, peak CK, Killip classification, serum creatinine, prior MI, moderate/severe MR and β-blocker.
CK, creatine kinase; IMR, ischaemic mitral regurgitation; IPTW, Inverse probability of treatment weighted; MI, myocardial infarction; RASI, renin–angiotensin system inhibitor.